BEDFORD, Mass.--(BUSINESS WIRE)--Dec. 2, 2014--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company
focused on the development and commercialization of innovative therapies
for diseases and conditions of the eye, today announced that Amar
Sawhney, Ph.D., President and Chief Executive Officer, will present a
corporate overview at the Oppenheimer 25th Annual Healthcare Conference
on Thursday, December 11, 2014 at 3:20 p.m. Eastern Time at the Crowne
Plaza Hotel in New York City.
The audio-only presentation will be accessible live on Ocular
Therapeutix’s website at investors.ocutx.com
under Investor Events and will be available for 90 days following the
presentation. A copy of the investor presentation will also be made
available upon written request.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
development and commercialization of innovative therapies for diseases
and conditions of the eye using its proprietary hydrogel platform
technology. Ocular Therapeutix's lead product candidates are in Phase 3
clinical development for post-surgical ocular inflammation and pain, and
Phase 2 clinical development for glaucoma and allergic conjunctivitis.
The Company is also evaluating sustained-release injectable anti-VEGF
drug depots for back-of-the-eye diseases. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal incisions
following cataract surgery.
Source: Ocular Therapeutix, Inc.
Investors:
Ocular Therapeutix, Inc.
Brad Smith
Chief
Financial Officer
bsmith@ocutx.com
or
Burns
McClellan on behalf of Ocular Therapeutix
Kimberly Minarovich,
212-213-0006
kminarovich@burnsmc.com
or
Media:
Scott
Corning
Vice President of Sales and Marketing
scorning@ocutx.com
